Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Viking Therapeutics reports Q3 EPS (13c), consensus (15c) » 17:07
10/28/20
10/28
17:07
10/28/20
17:07
VKTX

Viking Therapeutics

$5.29 /

-0.275 (-4.94%)

CEO Brian Lian stated,…

CEO Brian Lian stated, "Q3 at Viking was highlighted by continued pipeline progress, with enrollment now ongoing in two important clinical programs. The Phase 2b VOYAGE study of our lead NASH program, VK2809, continues and we anticipate completion of enrollment in the first half of 2021. In addition, at the EASL conference in August, we presented new data from the prior 12-week study of VK2809, demonstrating consistent liver fat reductions across high risk subgroups, as well as durable efficacy maintained four weeks after completion of dosing. With respect to our VK0214 program for X-linked adrenoleukodystrophy, we are excited to have moved this important program into the clinic, with the announcement of a Phase 1 SAD/MAD study in healthy subjects. Pending successful completion, in 2021 we plan to initiate a Phase 1b study in patients with X-ALD. Both of these clinical trials continue to advance despite disruptions resulting from the COVID-19 pandemic. Finally, to support both of these programs, we continue to judiciously manage our balance sheet and ended the quarter with $255M in cash."

ShowHide Related Items >><<
VKTX Viking Therapeutics
$5.29 /

-0.275 (-4.94%)

VKTX Viking Therapeutics
$5.29 /

-0.275 (-4.94%)

09/11/20 B. Riley Securities
Viking Therapeutics price target raised to $15 from $12 at B. Riley FBR
09/01/20 BTIG
Viking Therapeutics price target raised to $12 from $9 at BTIG
08/30/20 Chardan
Viking Therapeutics price target raised to $20 from $15 at Chardan
08/28/20 H.C. Wainwright
Viking Therapeutics price target raised to $21 from $18 at H.C. Wainwright
VKTX Viking Therapeutics
$5.29 /

-0.275 (-4.94%)

VKTX Viking Therapeutics
$5.29 /

-0.275 (-4.94%)

Over a month ago
Recommendations
Viking Therapeutics price target raised to $15 from $12 at B. Riley FBR » 08:33
09/11/20
09/11
08:33
09/11/20
08:33
VKTX

Viking Therapeutics

$5.89 /

-0.14 (-2.32%)

B. Riley FBR analyst…

B. Riley FBR analyst Mayank Mamtani raised the firm's price target on Viking Therapeutics to $15 from $12 and reiterates a Buy rating on the shares. The analyst is "encouraged" with the accumulating safety and tolerability data of VK2809. Continued progression of VK2809 and VK0214 through clinical development represents incremental de-risking of Viking's pipeline, Mamtani tells investors in a research note.

ShowHide Related Items >><<
VKTX Viking Therapeutics
$5.89 /

-0.14 (-2.32%)

VKTX Viking Therapeutics
$5.89 /

-0.14 (-2.32%)

09/01/20 BTIG
Viking Therapeutics price target raised to $12 from $9 at BTIG
08/30/20 Chardan
Viking Therapeutics price target raised to $20 from $15 at Chardan
08/28/20 H.C. Wainwright
Viking Therapeutics price target raised to $21 from $18 at H.C. Wainwright
06/04/20 BMO Capital
Viking Therapeutics initiated with an Outperform at BMO Capital
VKTX Viking Therapeutics
$5.89 /

-0.14 (-2.32%)

VKTX Viking Therapeutics
$5.89 /

-0.14 (-2.32%)

Hot Stocks
Viking Therapeutics initiates Phase 1 clinical trial of VK0214 » 07:06
09/09/20
09/09
07:06
09/09/20
07:06
VKTX

Viking Therapeutics

$5.86 /

-0.27 (-4.40%)

Viking Therapeutics…

Viking Therapeutics announced the initiation of a Phase 1 single ascending dose and multiple ascending dose clinical trial of VK0214, a novel, orally available thyroid receptor beta agonist in development as a potential treatment for X-linked adrenoleukodystrophy. Enrollment in this study is underway following clearance of the company's Investigational New Drug application by the United States FDA.

ShowHide Related Items >><<
VKTX Viking Therapeutics
$5.86 /

-0.27 (-4.40%)

VKTX Viking Therapeutics
$5.86 /

-0.27 (-4.40%)

09/01/20 BTIG
Viking Therapeutics price target raised to $12 from $9 at BTIG
08/30/20 Chardan
Viking Therapeutics price target raised to $20 from $15 at Chardan
08/28/20 H.C. Wainwright
Viking Therapeutics price target raised to $21 from $18 at H.C. Wainwright
06/04/20 BMO Capital
Viking Therapeutics initiated with an Outperform at BMO Capital
VKTX Viking Therapeutics
$5.86 /

-0.27 (-4.40%)

VKTX Viking Therapeutics
$5.86 /

-0.27 (-4.40%)

Conference/Events
Viking Therapeutics participates in a conference call hosted by B. Riley FBR » 11:25
09/02/20
09/02
11:25
09/02/20
11:25
VKTX

Viking Therapeutics

$6.42 /

-0.02 (-0.31%)

B. Riley FBR holds a…

B. Riley FBR holds a post-EASL investor conference call with management on September 2 at 12 pm.

ShowHide Related Items >><<
VKTX Viking Therapeutics
$6.42 /

-0.02 (-0.31%)

VKTX Viking Therapeutics
$6.42 /

-0.02 (-0.31%)

09/01/20 BTIG
Viking Therapeutics price target raised to $12 from $9 at BTIG
08/30/20 Chardan
Viking Therapeutics price target raised to $20 from $15 at Chardan
08/28/20 H.C. Wainwright
Viking Therapeutics price target raised to $21 from $18 at H.C. Wainwright
06/04/20 BMO Capital
Viking Therapeutics initiated with an Outperform at BMO Capital
VKTX Viking Therapeutics
$6.42 /

-0.02 (-0.31%)

VKTX Viking Therapeutics
$6.42 /

-0.02 (-0.31%)

Conference/Events
B. Riley FBR biotechnology analysts to hold an analyst/industry conference call » 09:23
09/02/20
09/02
09:23
09/02/20
09:23
CBAY

CymaBay

$6.24 /

-0.22 (-3.41%)

, VKTX

Viking Therapeutics

$6.44 /

-0.26 (-3.88%)

, AXLA

Axcella Health

$4.90 /

-0.11 (-2.20%)

Biotechnology Analysts…

Biotechnology Analysts provide a review of the recently-held European Association for Study of the Liver (EASL) Digital International Liver Congress 2020 on an Analyst/Industry conference call to be held on September 2.

ShowHide Related Items >><<
VKTX Viking Therapeutics
$6.44 /

-0.26 (-3.88%)

CBAY CymaBay
$6.24 /

-0.22 (-3.41%)

AXLA Axcella Health
$4.90 /

-0.11 (-2.20%)

CBAY CymaBay
$6.24 /

-0.22 (-3.41%)

08/27/20 Piper Sandler
Piper Sandler 'astonished' by seladelpar's long-term benefits
08/25/20 Citi
CymaBay price target raised to $9 from $7 at Citi
08/04/20 H.C. Wainwright
CymaBay price target raised to $13 from $9 at H.C. Wainwright
08/03/20 Cantor Fitzgerald
CymaBay price target raised to $20 from $15 at Cantor Fitzgerald
VKTX Viking Therapeutics
$6.44 /

-0.26 (-3.88%)

09/01/20 BTIG
Viking Therapeutics price target raised to $12 from $9 at BTIG
08/30/20 Chardan
Viking Therapeutics price target raised to $20 from $15 at Chardan
08/28/20 H.C. Wainwright
Viking Therapeutics price target raised to $21 from $18 at H.C. Wainwright
06/04/20 BMO Capital
Viking Therapeutics initiated with an Outperform at BMO Capital
AXLA Axcella Health
$4.90 /

-0.11 (-2.20%)

08/05/20 Piper Sandler
Axcella reported positive hepatic insufficiency data, says Piper Sandler
07/30/20 Piper Sandler
Axcella initiated with an Overweight at Piper Sandler
05/28/20
Fly Intel: Top five analyst initiations
05/28/20 Wedbush
Wedbush bullish on Axcella, initiates with an Outperform
VKTX Viking Therapeutics
$6.44 /

-0.26 (-3.88%)

CBAY CymaBay
$6.24 /

-0.22 (-3.41%)

AXLA Axcella Health
$4.90 /

-0.11 (-2.20%)

  • 14
    May
VKTX Viking Therapeutics
$6.44 /

-0.26 (-3.88%)

CBAY CymaBay
$6.24 /

-0.22 (-3.41%)

CBAY CymaBay
$6.24 /

-0.22 (-3.41%)

Conference/Events
Viking Therapeutics participates in a conference call hosted by B. Riley FBR » 11:30
09/01/20
09/01
11:30
09/01/20
11:30
VKTX

Viking Therapeutics

$6.57 /

-0.13 (-1.94%)

B. Riley FBR holds a…

B. Riley FBR holds a post-EASL investor conference call with management on September 2 at 12 pm.

ShowHide Related Items >><<
VKTX Viking Therapeutics
$6.57 /

-0.13 (-1.94%)

VKTX Viking Therapeutics
$6.57 /

-0.13 (-1.94%)

09/01/20 BTIG
Viking Therapeutics price target raised to $12 from $9 at BTIG
08/30/20 Chardan
Viking Therapeutics price target raised to $20 from $15 at Chardan
08/28/20 H.C. Wainwright
Viking Therapeutics price target raised to $21 from $18 at H.C. Wainwright
06/04/20 BMO Capital
Viking Therapeutics initiated with an Outperform at BMO Capital
VKTX Viking Therapeutics
$6.57 /

-0.13 (-1.94%)

VKTX Viking Therapeutics
$6.57 /

-0.13 (-1.94%)

Recommendations
Viking Therapeutics price target raised to $12 from $9 at BTIG » 07:17
09/01/20
09/01
07:17
09/01/20
07:17
VKTX

Viking Therapeutics

$6.70 /

-0.14 (-2.05%)

BTIG analyst Julian…

BTIG analyst Julian Harrison raised the firm's price target on Viking Therapeutics to $12 from $9 and keeps a Buy rating on the shares. The company showcased new data from the Phase 2a study of VK2809 as a podium presentation at EASL, and his position is that patients on VK2809 after a 12-week course followed by a 4-week holiday "look at least as good as patients on resmetirom immediately after a 12-week of dosing, the analyst tells investors in a research note. Harrison is raising his probability of success for VK2809 in NASH to 70% from 60%.

ShowHide Related Items >><<
VKTX Viking Therapeutics
$6.70 /

-0.14 (-2.05%)

VKTX Viking Therapeutics
$6.70 /

-0.14 (-2.05%)

08/30/20 Chardan
Viking Therapeutics price target raised to $20 from $15 at Chardan
08/28/20 H.C. Wainwright
Viking Therapeutics price target raised to $21 from $18 at H.C. Wainwright
06/04/20 BMO Capital
Viking Therapeutics initiated with an Outperform at BMO Capital
05/05/20 Chardan
Viking Therapeutics initiated with a Buy at Chardan
VKTX Viking Therapeutics
$6.70 /

-0.14 (-2.05%)

VKTX Viking Therapeutics
$6.70 /

-0.14 (-2.05%)

Recommendations
Viking Therapeutics price target raised to $20 from $15 at Chardan » 21:19
08/30/20
08/30
21:19
08/30/20
21:19
VKTX

Viking Therapeutics

$6.84 /

-0.6 (-8.06%)

Chardan analyst Michael…

Chardan analyst Michael Morabito raised the firm's price target on Viking Therapeutics to $20 from $15 and reiterates a Buy rating on the shares after the company presented additional data from its Phase II trial in patients with nonalcoholic fatty liver disease. The analyst views the week 16 follow-up data as "highly encouraging" for development of VK2809 in nonalcoholic steatohepatitis. The results demonstrate "remarkable durability" as patients receiving VK2809 at any dose continued to experience significant decreases from baseline in liver fat content compared to placebo, Morabito tells investors in a research note. This durability could provide an opportunity for more flexible dosing options to be explored for VK2809, says the analyst.

ShowHide Related Items >><<
VKTX Viking Therapeutics
$6.84 /

-0.6 (-8.06%)

VKTX Viking Therapeutics
$6.84 /

-0.6 (-8.06%)

08/28/20 H.C. Wainwright
Viking Therapeutics price target raised to $21 from $18 at H.C. Wainwright
06/04/20 BMO Capital
Viking Therapeutics initiated with an Outperform at BMO Capital
05/05/20 Chardan
Viking Therapeutics initiated with a Buy at Chardan
05/04/20 B. Riley Securities
Viking Therapeutics price target lowered to $12 from $16 at B. Riley FBR
VKTX Viking Therapeutics
$6.84 /

-0.6 (-8.06%)

VKTX Viking Therapeutics
$6.84 /

-0.6 (-8.06%)

Conference/Events
European Association for the Study of the Liver to hold a conference » 04:55
08/29/20
08/29
04:55
08/29/20
04:55
ABBV

AbbVie

$94.19 /

-0.09 (-0.10%)

, AKRO

Akero Therapeutics

$32.27 /

+0.67 (+2.12%)

, ALBO

Albireo Pharma

$27.15 /

-0.29 (-1.06%)

, AXLA

Axcella Health

$5.07 /

-0.13 (-2.50%)

, AZN

AstraZeneca

$55.66 /

-0.445 (-0.79%)

, BMY

Bristol-Myers

$62.37 /

-0.15 (-0.24%)

, CBAY

CymaBay

$6.14 /

+ (+0.00%)

, DRRX

Durect

$1.81 /

-0.08 (-4.23%)

, ENTA

Enanta

$51.25 /

+1.25 (+2.50%)

, ETNB

89bio

$37.76 /

+0.13 (+0.35%)

, GILD

Gilead

$65.26 /

-0.32 (-0.49%)

, GLMD

Galmed

$5.08 /

+0.02 (+0.40%)

, VKTX

Viking Therapeutics

$6.84 /

-0.6 (-8.06%)

, VBIV

VBI Vaccines

$3.99 /

-0.25 (-5.90%)

, PLRX

Pliant Therapeutics

$25.37 /

+1.01 (+4.15%)

, PFE

Pfizer

$37.90 /

+0.04 (+0.11%)

, NVS

Novartis

$86.64 /

-0.37 (-0.43%)

, NVO

Novo Nordisk

$65.85 /

-0.43 (-0.65%)

, NGM

NGM Biopharmaceuticals

$17.99 /

+0.14 (+0.78%)

, MIRM

Mirum Pharmaceuticals

$24.07 /

+0.47 (+1.99%)

, MDGL

Madrigal Pharmaceuticals

$106.62 /

+0.29 (+0.27%)

, LMNL

Liminal BioSciences

$11.79 /

+0.02 (+0.17%)

, ICPT

Intercept

$49.34 /

+0.62 (+1.27%)

, GNFT

Genfit

$4.92 /

-0.03 (-0.61%)

Digital International…

Digital International Liver Congress 2020 will be held on August 27-29. Webcast Link

ShowHide Related Items >><<
VKTX Viking Therapeutics
$6.84 /

-0.6 (-8.06%)

VBIV VBI Vaccines
$3.99 /

-0.25 (-5.90%)

PFE Pfizer
$37.90 /

+0.04 (+0.11%)

NVS Novartis
$86.64 /

-0.37 (-0.43%)

NVO Novo Nordisk
$65.85 /

-0.43 (-0.65%)

NGM NGM Biopharmaceuticals
$17.99 /

+0.14 (+0.78%)

MIRM Mirum Pharmaceuticals
$24.07 /

+0.47 (+1.99%)

MDGL Madrigal Pharmaceuticals
$106.62 /

+0.29 (+0.27%)

LMNL Liminal BioSciences
$11.79 /

+0.02 (+0.17%)

ICPT Intercept
$49.34 /

+0.62 (+1.27%)

GNFT Genfit
$4.92 /

-0.03 (-0.61%)

GLMD Galmed
$5.08 /

+0.02 (+0.40%)

GILD Gilead
$65.26 /

-0.32 (-0.49%)

ETNB 89bio
$37.76 /

+0.13 (+0.35%)

ENTA Enanta
$51.25 /

+1.25 (+2.50%)

DRRX Durect
$1.81 /

-0.08 (-4.23%)

CBAY CymaBay
$6.14 /

+ (+0.00%)

BMY Bristol-Myers
$62.37 /

-0.15 (-0.24%)

AZN AstraZeneca
$55.66 /

-0.445 (-0.79%)

AXLA Axcella Health
$5.07 /

-0.13 (-2.50%)

ALBO Albireo Pharma
$27.15 /

-0.29 (-1.06%)

AKRO Akero Therapeutics
$32.27 /

+0.67 (+2.12%)

ABBV AbbVie
$94.19 /

-0.09 (-0.10%)

ABBV AbbVie
$94.19 /

-0.09 (-0.10%)

08/24/20 H.C. Wainwright
Galapagos downgraded to Neutral from Buy at H.C. Wainwright
08/20/20 Morgan Stanley
AbbVie price target raised to $108 from $95 at Morgan Stanley
08/19/20 Piper Sandler
AbbVie commercial efforts easier after Gilead CRL, says Piper Sandler
08/19/20 Stifel
Galapagos price target lowered to $155 from $187 at Stifel
AKRO Akero Therapeutics
$32.27 /

+0.67 (+2.12%)

08/14/20 Piper Sandler
Piper sees 89bio's topline data beating Akero's in NASH
07/23/20 BTIG
89bio initiated with a Buy at BTIG
07/20/20 H.C. Wainwright
Akero Therapeutics price target raised to $62 from $45 at H.C. Wainwright
07/07/20 Chardan
Akero Therapeutics initiated with a Buy at Chardan
ALBO Albireo Pharma
$27.15 /

-0.29 (-1.06%)

08/19/20 H.C. Wainwright
Albireo Pharma price target lowered to $50 from $64 at H.C. Wainwright
07/30/20 Piper Sandler
Albireo Pharma initiated with an Overweight at Piper Sandler
07/16/20 H.C. Wainwright
Albireo price target raised to $64 at H.C. Wainwright after BOLD trial start
06/25/20
Fly Intel: Top five analyst initiations
AXLA Axcella Health
$5.07 /

-0.13 (-2.50%)

08/05/20 Piper Sandler
Axcella reported positive hepatic insufficiency data, says Piper Sandler
07/30/20 Piper Sandler
Axcella initiated with an Overweight at Piper Sandler
05/28/20
Fly Intel: Top five analyst initiations
05/28/20 Wedbush
Wedbush bullish on Axcella, initiates with an Outperform
AZN AstraZeneca
$55.66 /

-0.445 (-0.79%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
BMY Bristol-Myers
$62.37 /

-0.15 (-0.24%)

08/25/20 Piper Sandler
Bristol's trial miss has 'no financial impact' on Agios, says Piper Sandler
08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
CBAY CymaBay
$6.14 /

+ (+0.00%)

08/27/20 Piper Sandler
Piper Sandler 'astonished' by seladelpar's long-term benefits
08/25/20 Citi
CymaBay price target raised to $9 from $7 at Citi
08/04/20 H.C. Wainwright
CymaBay price target raised to $13 from $9 at H.C. Wainwright
08/03/20 Cantor Fitzgerald
CymaBay price target raised to $20 from $15 at Cantor Fitzgerald
DRRX Durect
$1.81 /

-0.08 (-4.23%)

07/30/20 Oppenheimer
Durect initiated with an Outperform at Oppenheimer
07/01/20 H.C. Wainwright
Durect alcoholic hepatitis efficacy could be seen in COVID, says H.C. Wainwright
06/29/20 B. Riley Securities
Durect should be bought on weakness from Gilead termination, says B. Riley FBR
06/29/20 H.C. Wainwright
Durect thesis unchanged after Gilead termination, says H.C. Wainwright
ENTA Enanta
$51.25 /

+1.25 (+2.50%)

08/28/20
Fly Intel: Top five analyst initiations
08/27/20 Roth Capital
Enanta resumed with a Buy at Roth Capital
08/25/20 Piper Sandler
Enanta initiated with an Overweight at Piper Sandler
07/27/20 JMP Securities
Enanta upgraded to Outperform from Market Perform at JMP Securities
ETNB 89bio
$37.76 /

+0.13 (+0.35%)

07/30/20 Piper Sandler
89bio initiated with an Overweight at Piper Sandler
07/23/20
Fly Intel: Top five analyst initiations
GILD Gilead
$65.26 /

-0.32 (-0.49%)

08/20/20 Truist
Gilead price target lowered to $67 from $74 at Truist
08/19/20 Piper Sandler
Piper Sandler trims Gilead target by $2, keeps Overweight rating
08/19/20 JPMorgan
Gilead CRL for filgotinib 'near worst case scenario,' says JPMorgan
GLMD Galmed
$5.08 /

+0.02 (+0.40%)

05/22/20
Fly Intel: Top five analyst downgrades
05/22/20 B. Riley Securities
B. Riley FBR downgrades Galmed, cuts target to $8 from $11
05/22/20 B. Riley Securities
Galmed downgraded to Neutral from Buy at B. Riley FBR
05/15/20 H.C. Wainwright
Galmed price target lowered to $29 from $34 at H.C. Wainwright
VKTX Viking Therapeutics
$6.84 /

-0.6 (-8.06%)

08/28/20 H.C. Wainwright
Viking Therapeutics price target raised to $21 from $18 at H.C. Wainwright
06/04/20 BMO Capital
Viking Therapeutics initiated with an Outperform at BMO Capital
05/05/20 Chardan
Viking Therapeutics initiated with a Buy at Chardan
05/04/20 B. Riley Securities
Viking Therapeutics price target lowered to $12 from $16 at B. Riley FBR
VBIV VBI Vaccines
$3.99 /

-0.25 (-5.90%)

08/27/20 Raymond James
VBI Vaccines upgraded to Strong Buy from Outperform at Raymond James
08/27/20 Oppenheimer
VBI Vaccines' COVID vaccine has potential to be best-in-class, says Oppenheimer
08/26/20 Raymond James
VBI Vaccines upgraded to Strong Buy from Outperform at Raymond James
06/23/20 Oppenheimer
VBI Vaccines price target raised to $8 from $5 at Oppenheimer
PLRX Pliant Therapeutics
$25.37 /

+1.01 (+4.15%)

08/11/20 Piper Sandler
Pliant Therapeutics' approach to fibrotic diseases best in industry, says Piper
06/29/20 Needham
Pliant Therapeutics initiated with a Buy at Needham
06/29/20 Cowen
Pliant Therapeutics initiated with an Outperform at Cowen
06/29/20 Citi
Pliant Therapeutics initiated with a Buy at Citi
PFE Pfizer
$37.90 /

+0.04 (+0.11%)

08/27/20 Chardan
Moderna vaccine showed differentiation from BioNTech/Pfizer's, says Chardan
08/25/20 Truist
Forte Biosciences initiated with a Buy at Truist
08/24/20 SVB Leerink
SVB Leerink continues to view Alexion as good M&A fit for number of suitors
08/21/20 Mizuho
Pfizer COVID vaccine data 'ok encouraging,' says Mizuho
NVS Novartis
$86.64 /

-0.37 (-0.43%)

08/27/20 Piper Sandler
Intercept's OCA 'comes out on top' at EASL, says Piper Sandler
08/18/20 Raymond James
Teva could pay damages nearing $1B in DOJ FCA action, says Raymond James
08/12/20 JPMorgan
Novartis price target lowered to CHF 82 from CHF 84 at JPMorgan
07/28/20 Morgan Stanley
Novartis price target raised to CHF 93 from CHF 91 at Morgan Stanley
NVO Novo Nordisk
$65.85 /

-0.43 (-0.65%)

08/18/20 UBS
Novo Nordisk price target lowered to DKK 415 from DKK 425 at UBS
08/03/20 Morgan Stanley
Novo Nordisk price target lowered to DKK 425 from DKK 435 at Morgan Stanley
07/06/20 BofA
Novo Nordisk downgraded to Neutral from Buy at BofA
06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
NGM NGM Biopharmaceuticals
$17.99 /

+0.14 (+0.78%)

08/12/20 Piper Sandler
NGM Biopharmaceuticals' four pipeline programs underappreciated, says Piper
07/30/20 Piper Sandler
NGM Biopharmaceuticals initiated with an Overweight at Piper Sandler
07/07/20 Chardan
NGM Biopharmaceuticals initiated with a Buy at Chardan
06/04/20 BMO Capital
NGM Biopharmaceuticals initiated with an Outperform at BMO Capital
MIRM Mirum Pharmaceuticals
$24.07 /

+0.47 (+1.99%)

08/07/20 Raymond James
Mirum Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
08/07/20 Raymond James
Mirum Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
08/03/20
Fly Intel: Top five analyst initiations
08/03/20 H.C. Wainwright
Mirum Pharmaceuticals initiated with a Buy at H.C. Wainwright
MDGL Madrigal Pharmaceuticals
$106.62 /

+0.29 (+0.27%)

07/30/20 Piper Sandler
Madrigal Pharmaceuticals initiated with an Overweight at Piper Sandler
06/04/20 BMO Capital
Madrigal Pharmaceuticals initiated with a Market Perform at BMO Capital
05/22/20 B. Riley Securities
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
05/08/20 H.C. Wainwright
Madrigal Pharmaceuticals price target lowered to $168 from $215 at H.C. Wainwright
LMNL Liminal BioSciences
$11.79 /

+0.02 (+0.17%)

ICPT Intercept
$49.34 /

+0.62 (+1.27%)

08/28/20 Piper Sandler
Piper says Intercept data continues to tilt risk/benefit argument raised in CRL
08/10/20 Stifel
Intercept price target raised to $56 from $51 at Stifel
08/10/20 Piper Sandler
Piper Sandler confident in success of Intercept's OCA approval in 2021
GNFT Genfit
$4.92 /

-0.03 (-0.61%)

08/05/20 H.C. Wainwright
Lancet publication 'strong validation' Genfit's NIS4, says H.C. Wainwright
07/23/20 H.C. Wainwright
Genfit price target lowered to $8 from $11 at H.C. Wainwright
07/23/20
Fly Intel: Top five analyst upgrades
07/23/20 Stifel
Genfit upgraded to Buy from Hold at Stifel
VKTX Viking Therapeutics
$6.84 /

-0.6 (-8.06%)

PLRX Pliant Therapeutics
$25.37 /

+1.01 (+4.15%)

PFE Pfizer
$37.90 /

+0.04 (+0.11%)

NVS Novartis
$86.64 /

-0.37 (-0.43%)

NVO Novo Nordisk
$65.85 /

-0.43 (-0.65%)

NGM NGM Biopharmaceuticals
$17.99 /

+0.14 (+0.78%)

MIRM Mirum Pharmaceuticals
$24.07 /

+0.47 (+1.99%)

MDGL Madrigal Pharmaceuticals
$106.62 /

+0.29 (+0.27%)

ICPT Intercept
$49.34 /

+0.62 (+1.27%)

GLMD Galmed
$5.08 /

+0.02 (+0.40%)

GILD Gilead
$65.26 /

-0.32 (-0.49%)

ETNB 89bio
$37.76 /

+0.13 (+0.35%)

ENTA Enanta
$51.25 /

+1.25 (+2.50%)

DRRX Durect
$1.81 /

-0.08 (-4.23%)

CBAY CymaBay
$6.14 /

+ (+0.00%)

BMY Bristol-Myers
$62.37 /

-0.15 (-0.24%)

AZN AstraZeneca
$55.66 /

-0.445 (-0.79%)

AXLA Axcella Health
$5.07 /

-0.13 (-2.50%)

ALBO Albireo Pharma
$27.15 /

-0.29 (-1.06%)

AKRO Akero Therapeutics
$32.27 /

+0.67 (+2.12%)

ABBV AbbVie
$94.19 /

-0.09 (-0.10%)

  • 18
    Aug
  • 08
    Jul
  • 08
    Jul
  • 03
    Jun
  • 14
    May
  • 22
    Apr
  • 30
    Jan
  • 09
    Jan
  • 11
    Dec
  • 11
    Nov
  • 19
    Sep
VBIV VBI Vaccines
$3.99 /

-0.25 (-5.90%)

PFE Pfizer
$37.90 /

+0.04 (+0.11%)

NVS Novartis
$86.64 /

-0.37 (-0.43%)

NVO Novo Nordisk
$65.85 /

-0.43 (-0.65%)

GILD Gilead
$65.26 /

-0.32 (-0.49%)

BMY Bristol-Myers
$62.37 /

-0.15 (-0.24%)

AZN AstraZeneca
$55.66 /

-0.445 (-0.79%)

ABBV AbbVie
$94.19 /

-0.09 (-0.10%)

VKTX Viking Therapeutics
$6.84 /

-0.6 (-8.06%)

VBIV VBI Vaccines
$3.99 /

-0.25 (-5.90%)

PLRX Pliant Therapeutics
$25.37 /

+1.01 (+4.15%)

PFE Pfizer
$37.90 /

+0.04 (+0.11%)

NVS Novartis
$86.64 /

-0.37 (-0.43%)

NVO Novo Nordisk
$65.85 /

-0.43 (-0.65%)

NGM NGM Biopharmaceuticals
$17.99 /

+0.14 (+0.78%)

ICPT Intercept
$49.34 /

+0.62 (+1.27%)

GNFT Genfit
$4.92 /

-0.03 (-0.61%)

GILD Gilead
$65.26 /

-0.32 (-0.49%)

ETNB 89bio
$37.76 /

+0.13 (+0.35%)

DRRX Durect
$1.81 /

-0.08 (-4.23%)

CBAY CymaBay
$6.14 /

+ (+0.00%)

BMY Bristol-Myers
$62.37 /

-0.15 (-0.24%)

AZN AstraZeneca
$55.66 /

-0.445 (-0.79%)

AKRO Akero Therapeutics
$32.27 /

+0.67 (+2.12%)

ABBV AbbVie
$94.19 /

-0.09 (-0.10%)

VBIV VBI Vaccines
$3.99 /

-0.25 (-5.90%)

PFE Pfizer
$37.90 /

+0.04 (+0.11%)

NVS Novartis
$86.64 /

-0.37 (-0.43%)

NVO Novo Nordisk
$65.85 /

-0.43 (-0.65%)

NGM NGM Biopharmaceuticals
$17.99 /

+0.14 (+0.78%)

GILD Gilead
$65.26 /

-0.32 (-0.49%)

DRRX Durect
$1.81 /

-0.08 (-4.23%)

CBAY CymaBay
$6.14 /

+ (+0.00%)

BMY Bristol-Myers
$62.37 /

-0.15 (-0.24%)

AZN AstraZeneca
$55.66 /

-0.445 (-0.79%)

ABBV AbbVie
$94.19 /

-0.09 (-0.10%)

Conference/Events
European Association for the Study of the Liver to hold a conference » 09:12
08/28/20
08/28
09:12
08/28/20
09:12
ABBV

AbbVie

$94.28 /

-0.04 (-0.04%)

, AKRO

Akero Therapeutics

$31.60 /

-2.06 (-6.12%)

, ALBO

Albireo Pharma

$27.44 /

-0.84 (-2.97%)

, AXLA

Axcella Health

$5.20 /

-0.13 (-2.44%)

, AZN

AstraZeneca

$56.11 /

-0.885 (-1.55%)

, BMY

Bristol-Myers

$62.52 /

+0.23 (+0.37%)

, CBAY

CymaBay

$6.14 /

-0.33 (-5.10%)

, DRRX

Durect

$1.89 /

-0.1 (-5.03%)

, ENTA

Enanta

$50.00 /

+0.2 (+0.40%)

, ETNB

89bio

$37.63 /

-0.63 (-1.65%)

, GILD

Gilead

$65.58 /

-0.01 (-0.02%)

, GLMD

Galmed

$5.06 /

-0.08 (-1.56%)

, VKTX

Viking Therapeutics

$7.44 /

-0.67 (-8.26%)

, VBIV

VBI Vaccines

$4.24 /

+1.035 (+32.29%)

, PLRX

Pliant Therapeutics

$24.36 /

-0.27 (-1.10%)

, PFE

Pfizer

$37.86 /

-0.21 (-0.55%)

, NVS

Novartis

$87.01 /

+0.01 (+0.01%)

, NVO

Novo Nordisk

$66.28 /

-0.475 (-0.71%)

, NGM

NGM Biopharmaceuticals

$17.85 /

-0.43 (-2.35%)

, MIRM

Mirum Pharmaceuticals

$23.60 /

-0.31 (-1.30%)

, MDGL

Madrigal Pharmaceuticals

$106.33 /

+1.03 (+0.98%)

, LMNL

Liminal BioSciences

$11.77 /

-0.5 (-4.07%)

, ICPT

Intercept

$48.72 /

+0.25 (+0.52%)

, GNFT

Genfit

$4.95 /

-0.07 (-1.39%)

Digital International…

Digital International Liver Congress 2020 will be held on August 27-29. Webcast Link

ShowHide Related Items >><<
VKTX Viking Therapeutics
$7.44 /

-0.67 (-8.26%)

VBIV VBI Vaccines
$4.24 /

+1.035 (+32.29%)

PFE Pfizer
$37.86 /

-0.21 (-0.55%)

NVS Novartis
$87.01 /

+0.01 (+0.01%)

NVO Novo Nordisk
$66.28 /

-0.475 (-0.71%)

NGM NGM Biopharmaceuticals
$17.85 /

-0.43 (-2.35%)

MIRM Mirum Pharmaceuticals
$23.60 /

-0.31 (-1.30%)

MDGL Madrigal Pharmaceuticals
$106.33 /

+1.03 (+0.98%)

LMNL Liminal BioSciences
$11.77 /

-0.5 (-4.07%)

ICPT Intercept
$48.72 /

+0.25 (+0.52%)

GNFT Genfit
$4.95 /

-0.07 (-1.39%)

GLMD Galmed
$5.06 /

-0.08 (-1.56%)

GILD Gilead
$65.58 /

-0.01 (-0.02%)

ETNB 89bio
$37.63 /

-0.63 (-1.65%)

ENTA Enanta
$50.00 /

+0.2 (+0.40%)

DRRX Durect
$1.89 /

-0.1 (-5.03%)

CBAY CymaBay
$6.14 /

-0.33 (-5.10%)

BMY Bristol-Myers
$62.52 /

+0.23 (+0.37%)

AZN AstraZeneca
$56.11 /

-0.885 (-1.55%)

AXLA Axcella Health
$5.20 /

-0.13 (-2.44%)

ALBO Albireo Pharma
$27.44 /

-0.84 (-2.97%)

AKRO Akero Therapeutics
$31.60 /

-2.06 (-6.12%)

ABBV AbbVie
$94.28 /

-0.04 (-0.04%)

ABBV AbbVie
$94.28 /

-0.04 (-0.04%)

08/24/20 H.C. Wainwright
Galapagos downgraded to Neutral from Buy at H.C. Wainwright
08/20/20 Morgan Stanley
AbbVie price target raised to $108 from $95 at Morgan Stanley
08/19/20 Piper Sandler
AbbVie commercial efforts easier after Gilead CRL, says Piper Sandler
08/19/20 Stifel
Galapagos price target lowered to $155 from $187 at Stifel
AKRO Akero Therapeutics
$31.60 /

-2.06 (-6.12%)

08/14/20 Piper Sandler
Piper sees 89bio's topline data beating Akero's in NASH
07/23/20 BTIG
89bio initiated with a Buy at BTIG
07/20/20 H.C. Wainwright
Akero Therapeutics price target raised to $62 from $45 at H.C. Wainwright
07/07/20 Chardan
Akero Therapeutics initiated with a Buy at Chardan
ALBO Albireo Pharma
$27.44 /

-0.84 (-2.97%)

08/19/20 H.C. Wainwright
Albireo Pharma price target lowered to $50 from $64 at H.C. Wainwright
07/30/20 Piper Sandler
Albireo Pharma initiated with an Overweight at Piper Sandler
07/16/20 H.C. Wainwright
Albireo price target raised to $64 at H.C. Wainwright after BOLD trial start
06/25/20
Fly Intel: Top five analyst initiations
AXLA Axcella Health
$5.20 /

-0.13 (-2.44%)

08/05/20 Piper Sandler
Axcella reported positive hepatic insufficiency data, says Piper Sandler
07/30/20 Piper Sandler
Axcella initiated with an Overweight at Piper Sandler
05/28/20
Fly Intel: Top five analyst initiations
05/28/20 Wedbush
Wedbush bullish on Axcella, initiates with an Outperform
AZN AstraZeneca
$56.11 /

-0.885 (-1.55%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
BMY Bristol-Myers
$62.52 /

+0.23 (+0.37%)

08/25/20 Piper Sandler
Bristol's trial miss has 'no financial impact' on Agios, says Piper Sandler
08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
CBAY CymaBay
$6.14 /

-0.33 (-5.10%)

08/27/20 Piper Sandler
Piper Sandler 'astonished' by seladelpar's long-term benefits
08/25/20 Citi
CymaBay price target raised to $9 from $7 at Citi
08/04/20 H.C. Wainwright
CymaBay price target raised to $13 from $9 at H.C. Wainwright
08/03/20 Cantor Fitzgerald
CymaBay price target raised to $20 from $15 at Cantor Fitzgerald
DRRX Durect
$1.89 /

-0.1 (-5.03%)

07/30/20 Oppenheimer
Durect initiated with an Outperform at Oppenheimer
07/01/20 H.C. Wainwright
Durect alcoholic hepatitis efficacy could be seen in COVID, says H.C. Wainwright
06/29/20 B. Riley Securities
Durect should be bought on weakness from Gilead termination, says B. Riley FBR
06/29/20 H.C. Wainwright
Durect thesis unchanged after Gilead termination, says H.C. Wainwright
ENTA Enanta
$50.00 /

+0.2 (+0.40%)

08/27/20 Roth Capital
Enanta resumed with a Buy at Roth Capital
08/25/20 Piper Sandler
Enanta initiated with an Overweight at Piper Sandler
07/27/20 JMP Securities
Enanta upgraded to Outperform from Market Perform at JMP Securities
03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
ETNB 89bio
$37.63 /

-0.63 (-1.65%)

07/30/20 Piper Sandler
89bio initiated with an Overweight at Piper Sandler
07/23/20
Fly Intel: Top five analyst initiations
GILD Gilead
$65.58 /

-0.01 (-0.02%)

08/20/20 Truist
Gilead price target lowered to $67 from $74 at Truist
08/19/20 Piper Sandler
Piper Sandler trims Gilead target by $2, keeps Overweight rating
08/19/20 JPMorgan
Gilead CRL for filgotinib 'near worst case scenario,' says JPMorgan
GLMD Galmed
$5.06 /

-0.08 (-1.56%)

05/22/20
Fly Intel: Top five analyst downgrades
05/22/20 B. Riley Securities
B. Riley FBR downgrades Galmed, cuts target to $8 from $11
05/22/20 B. Riley Securities
Galmed downgraded to Neutral from Buy at B. Riley FBR
05/15/20 H.C. Wainwright
Galmed price target lowered to $29 from $34 at H.C. Wainwright
VKTX Viking Therapeutics
$7.44 /

-0.67 (-8.26%)

08/28/20 H.C. Wainwright
Viking Therapeutics price target raised to $21 from $18 at H.C. Wainwright
06/04/20 BMO Capital
Viking Therapeutics initiated with an Outperform at BMO Capital
05/05/20 Chardan
Viking Therapeutics initiated with a Buy at Chardan
05/04/20 B. Riley Securities
Viking Therapeutics price target lowered to $12 from $16 at B. Riley FBR
VBIV VBI Vaccines
$4.24 /

+1.035 (+32.29%)

08/27/20 Raymond James
VBI Vaccines upgraded to Strong Buy from Outperform at Raymond James
08/27/20 Oppenheimer
VBI Vaccines' COVID vaccine has potential to be best-in-class, says Oppenheimer
08/26/20 Raymond James
VBI Vaccines upgraded to Strong Buy from Outperform at Raymond James
06/23/20 Oppenheimer
VBI Vaccines price target raised to $8 from $5 at Oppenheimer
PLRX Pliant Therapeutics
$24.36 /

-0.27 (-1.10%)

08/11/20 Piper Sandler
Pliant Therapeutics' approach to fibrotic diseases best in industry, says Piper
06/29/20 Needham
Pliant Therapeutics initiated with a Buy at Needham
06/29/20 Cowen
Pliant Therapeutics initiated with an Outperform at Cowen
06/29/20 Citi
Pliant Therapeutics initiated with a Buy at Citi
PFE Pfizer
$37.86 /

-0.21 (-0.55%)

08/27/20 Chardan
Moderna vaccine showed differentiation from BioNTech/Pfizer's, says Chardan
08/25/20 Truist
Forte Biosciences initiated with a Buy at Truist
08/24/20 SVB Leerink
SVB Leerink continues to view Alexion as good M&A fit for number of suitors
08/21/20 Mizuho
Pfizer COVID vaccine data 'ok encouraging,' says Mizuho
NVS Novartis
$87.01 /

+0.01 (+0.01%)

08/27/20 Piper Sandler
Intercept's OCA 'comes out on top' at EASL, says Piper Sandler
08/18/20 Raymond James
Teva could pay damages nearing $1B in DOJ FCA action, says Raymond James
08/12/20 JPMorgan
Novartis price target lowered to CHF 82 from CHF 84 at JPMorgan
07/28/20 Morgan Stanley
Novartis price target raised to CHF 93 from CHF 91 at Morgan Stanley
NVO Novo Nordisk
$66.28 /

-0.475 (-0.71%)

08/18/20 UBS
Novo Nordisk price target lowered to DKK 415 from DKK 425 at UBS
08/03/20 Morgan Stanley
Novo Nordisk price target lowered to DKK 425 from DKK 435 at Morgan Stanley
07/06/20 BofA
Novo Nordisk downgraded to Neutral from Buy at BofA
06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
NGM NGM Biopharmaceuticals
$17.85 /

-0.43 (-2.35%)

08/12/20 Piper Sandler
NGM Biopharmaceuticals' four pipeline programs underappreciated, says Piper
07/30/20 Piper Sandler
NGM Biopharmaceuticals initiated with an Overweight at Piper Sandler
07/07/20 Chardan
NGM Biopharmaceuticals initiated with a Buy at Chardan
06/04/20 BMO Capital
NGM Biopharmaceuticals initiated with an Outperform at BMO Capital
MIRM Mirum Pharmaceuticals
$23.60 /

-0.31 (-1.30%)

08/07/20 Raymond James
Mirum Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
08/07/20 Raymond James
Mirum Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
08/03/20
Fly Intel: Top five analyst initiations
08/03/20 H.C. Wainwright
Mirum Pharmaceuticals initiated with a Buy at H.C. Wainwright
MDGL Madrigal Pharmaceuticals
$106.33 /

+1.03 (+0.98%)

07/30/20 Piper Sandler
Madrigal Pharmaceuticals initiated with an Overweight at Piper Sandler
06/04/20 BMO Capital
Madrigal Pharmaceuticals initiated with a Market Perform at BMO Capital
05/22/20 B. Riley Securities
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
05/08/20 H.C. Wainwright
Madrigal Pharmaceuticals price target lowered to $168 from $215 at H.C. Wainwright
LMNL Liminal BioSciences
$11.77 /

-0.5 (-4.07%)

ICPT Intercept
$48.72 /

+0.25 (+0.52%)

08/10/20 Stifel
Intercept price target raised to $56 from $51 at Stifel
08/10/20 Piper Sandler
Piper Sandler confident in success of Intercept's OCA approval in 2021
07/30/20 Piper Sandler
Intercept initiated with an Overweight at Piper Sandler
GNFT Genfit
$4.95 /

-0.07 (-1.39%)

08/05/20 H.C. Wainwright
Lancet publication 'strong validation' Genfit's NIS4, says H.C. Wainwright
07/23/20 H.C. Wainwright
Genfit price target lowered to $8 from $11 at H.C. Wainwright
07/23/20
Fly Intel: Top five analyst upgrades
07/23/20 Stifel
Genfit upgraded to Buy from Hold at Stifel
VKTX Viking Therapeutics
$7.44 /

-0.67 (-8.26%)

PLRX Pliant Therapeutics
$24.36 /

-0.27 (-1.10%)

PFE Pfizer
$37.86 /

-0.21 (-0.55%)

NVS Novartis
$87.01 /

+0.01 (+0.01%)

NVO Novo Nordisk
$66.28 /

-0.475 (-0.71%)

NGM NGM Biopharmaceuticals
$17.85 /

-0.43 (-2.35%)

MIRM Mirum Pharmaceuticals
$23.60 /

-0.31 (-1.30%)

MDGL Madrigal Pharmaceuticals
$106.33 /

+1.03 (+0.98%)

ICPT Intercept
$48.72 /

+0.25 (+0.52%)

GLMD Galmed
$5.06 /

-0.08 (-1.56%)

GILD Gilead
$65.58 /

-0.01 (-0.02%)

ETNB 89bio
$37.63 /

-0.63 (-1.65%)

ENTA Enanta
$50.00 /

+0.2 (+0.40%)

DRRX Durect
$1.89 /

-0.1 (-5.03%)

CBAY CymaBay
$6.14 /

-0.33 (-5.10%)

BMY Bristol-Myers
$62.52 /

+0.23 (+0.37%)

AZN AstraZeneca
$56.11 /

-0.885 (-1.55%)

AXLA Axcella Health
$5.20 /

-0.13 (-2.44%)

ALBO Albireo Pharma
$27.44 /

-0.84 (-2.97%)

AKRO Akero Therapeutics
$31.60 /

-2.06 (-6.12%)

ABBV AbbVie
$94.28 /

-0.04 (-0.04%)

  • 18
    Aug
  • 08
    Jul
  • 08
    Jul
  • 03
    Jun
  • 14
    May
  • 22
    Apr
  • 30
    Jan
  • 09
    Jan
  • 11
    Dec
  • 11
    Nov
  • 19
    Sep
VBIV VBI Vaccines
$4.24 /

+1.035 (+32.29%)

PFE Pfizer
$37.86 /

-0.21 (-0.55%)

NVS Novartis
$87.01 /

+0.01 (+0.01%)

NVO Novo Nordisk
$66.28 /

-0.475 (-0.71%)

GILD Gilead
$65.58 /

-0.01 (-0.02%)

BMY Bristol-Myers
$62.52 /

+0.23 (+0.37%)

AZN AstraZeneca
$56.11 /

-0.885 (-1.55%)

ABBV AbbVie
$94.28 /

-0.04 (-0.04%)

VKTX Viking Therapeutics
$7.44 /

-0.67 (-8.26%)

VBIV VBI Vaccines
$4.24 /

+1.035 (+32.29%)

PLRX Pliant Therapeutics
$24.36 /

-0.27 (-1.10%)

PFE Pfizer
$37.86 /

-0.21 (-0.55%)

NVS Novartis
$87.01 /

+0.01 (+0.01%)

NVO Novo Nordisk
$66.28 /

-0.475 (-0.71%)

NGM NGM Biopharmaceuticals
$17.85 /

-0.43 (-2.35%)

ICPT Intercept
$48.72 /

+0.25 (+0.52%)

GNFT Genfit
$4.95 /

-0.07 (-1.39%)

GILD Gilead
$65.58 /

-0.01 (-0.02%)

ETNB 89bio
$37.63 /

-0.63 (-1.65%)

DRRX Durect
$1.89 /

-0.1 (-5.03%)

CBAY CymaBay
$6.14 /

-0.33 (-5.10%)

BMY Bristol-Myers
$62.52 /

+0.23 (+0.37%)

AZN AstraZeneca
$56.11 /

-0.885 (-1.55%)

AKRO Akero Therapeutics
$31.60 /

-2.06 (-6.12%)

ABBV AbbVie
$94.28 /

-0.04 (-0.04%)

VBIV VBI Vaccines
$4.24 /

+1.035 (+32.29%)

PFE Pfizer
$37.86 /

-0.21 (-0.55%)

NVS Novartis
$87.01 /

+0.01 (+0.01%)

NVO Novo Nordisk
$66.28 /

-0.475 (-0.71%)

NGM NGM Biopharmaceuticals
$17.85 /

-0.43 (-2.35%)

GILD Gilead
$65.58 /

-0.01 (-0.02%)

DRRX Durect
$1.89 /

-0.1 (-5.03%)

CBAY CymaBay
$6.14 /

-0.33 (-5.10%)

BMY Bristol-Myers
$62.52 /

+0.23 (+0.37%)

AZN AstraZeneca
$56.11 /

-0.885 (-1.55%)

ABBV AbbVie
$94.28 /

-0.04 (-0.04%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.